In this section:

07 October 2019

Skyrizi (Risankizumab) - New Biologic Treatment Approved for Psoriasis in Scotland

Skyrizi (Risankizumab) has been recommended for the treatment of moderate to severe plaque psoriasis in adults in Scotland.

The Scottish Medicines Consortium (SMC) has today published its decision to recommend the biologic medicine, Skyrizi (Risankizumab), as a treatment for adults with moderate to severe plaque psoriasis in Scotland. This brings Scotland in line with England and Wales where the National Institute for Health and Care Excellence (NICE) approved Skyrizi for the treatment of psoriasis in August 2019.

Skyrizi may be prescribed to adult patients who have not responded to conventional systemic therapies (including ciclosporin, methotrexate and phototherapy), or who cannot tolerate these treatments.

How does Skyrizi work?

Skyrizi works by blocking the action of interleukin-23 (IL-23), a chemical ‘messenger’ in the immune system which signals other cells to cause inflammation. In people with psoriasis, the immune system is overactive and creates too much inflammation, which leads to the development of psoriasis symptoms. By blocking IL-23, Skyrizi aims to prevent some of that inflammation from occurring, leading to an improvement in psoriasis for some people who take it.

How is Skyrizi taken?

Skyrizi is taken by injection at a dose of 150mg (two injections of 75mg each) at weeks 0 and 4, and every 12 weeks from then on.

We will be publishing more information on Skyrizi in the near future. If you have any further questions, please get in touch.

The Psoriasis Association is the UK's leading national charity and membership organisation for people affected by psoriasis – patients, families, carers and health professionals Read More >

Get in touch

The Psoriasis Association Dick Coles House 2 Queensbridge Northampton NN4 7BF


Tel :
01604 251 620
WhatsApp :
Registered with Fundraising Regulator -

© The Psoriasis Association Charitable Incorporated Organisation Number: 1180666 Scotland: SC049563 Privacy PolicyCookies

Site by Spoken Image | glitterfish

We use cookies to help us provide you with a better service, but do not track anything that can be used to personally identify you.

If you prefer us not to set these cookies, please visit our Cookie Settings page or continue browsing our site to accept them.